Intellia Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Intellia Therapeutics generated cash of -$394,086,000, which is less than the previous year. Cash used in financing activities reached the amount of $130,323,000 last year. Net change in cash is therefore -$295,110,000.
Cash Flow
| 2015 | -1.76M | -2.55M | 70.28M |
|---|---|---|---|
| 2016 | 36.10M | -6.16M | 167.30M |
| 2017 | -65.27M | -10.09M | 142.98M |
| 2018 | -61.25M | -260.78M | 40.21M |
| 2019 | -103.24M | 25.17M | 76.43M |
| 2020 | -49.91M | -214.48M | 371.77M |
| 2021 | -225.03M | -550.77M | 736.68M |
| 2022 | -333.28M | 160.30M | 582.95M |
| 2023 | -394.08M | -31.34M | 130.32M |
NTLA Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 535.46M | 125.48M | 164.60M | 57.22M | 58.85M | 340.67M | 273.06M | 75.81M | 9.84M |
Operating activities | |||||||||
Net income | -481.19M | -474.18M | -267.89M | -134.23M | -99.53M | -85.34M | -67.54M | -31.63M | -12.39M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 8.97M | 7.57M | 6.89M | 6.31M | 5.58M | 4.46M | 2.99M | 1.10M | 328K |
Stock-based compensation expense | 134.05M | 91.4M | 47.00M | 19.90M | 15.09M | 0 | 15.32M | 6.71M | 1.30M |
| Deferred income tax benefit | 134.05M | 91.4M | 47.00M | 19.90M | 15.09M | 0 | 15.32M | 6.71M | 1.30M |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -32.68M | -1.73M | 99K | 2.49M | 2.92M | 2.92M | -4.01M | -5.45M | -1.01M |
Inventories | -19.50M | 0 | 7.82M | 4.86M | 1.65M | 3.95M | 1.27M | -4.39M | 0 |
Accounts payable | 2.52M | -4.58M | 529K | 5.06M | 1.88M | 232K | -488K | 1.78M | 335K |
Cash generated by operating activities | -394.08M | -333.28M | -225.03M | -49.91M | -103.24M | -61.25M | -65.27M | 36.10M | -1.76M |
Investing activities | |||||||||
Purchases Of Investments | -904.46M | -429.03M | -1.02B | -473.70M | -297.03M | -254.55M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -13.98M | -58.39M | -12.75M | -3.58M | -6.79M | -6.35M | -10.09M | -6.16M | -2.55M |
Acquisitions Net | 0 | -44.68M | -3M | 210.90M | -31.97M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -31.34M | 160.30M | -550.77M | -214.48M | 25.17M | -260.78M | -10.09M | -6.16M | -2.55M |
Financing activities | |||||||||
Common Stock Issued | 119.79M | 565.78M | 736.68M | 358.64M | 72.25M | 28.97M | 141M | 0 | 74.05M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.67M |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 130.32M | 582.95M | 736.68M | 371.77M | 76.43M | 40.21M | 142.98M | 167.30M | 70.28M |
Net Change In Cash | -295.11M | 409.97M | -39.12M | 107.38M | -1.63M | -281.82M | 67.61M | 197.24M | 65.97M |
Cash at end of period | 240.35M | 535.46M | 125.48M | 164.60M | 57.22M | 58.85M | 340.67M | 273.06M | 75.81M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |